Oxybutynin: an overview of the available formulations.

Article Details

Citation

Copy to clipboard

McCrery RJ, Appell RA

Oxybutynin: an overview of the available formulations.

Ther Clin Risk Manag. 2006 Mar;2(1):19-24.

PubMed ID

18360578 [ View in PubMed

]

Abstract

Overactive bladder (OAB) is a common problem presented to by physicians. Standard treatment with antimuscarinic medication is directed at suppressing involuntary detrusor contractions by blocking the binding of acetylcholine to muscarinic receptors in the bladder. Oxybutynin chloride is the first of several antimuscarinic medications to be marketed for OAB. Although efficacious for treating OAB symptoms, the side effects and suboptimal dosing regimen decrease its utility. To improve patient compliance and tolerability, alternative delivery systems for oxybutynin have subsequently been developed and include a once-daily formulation and a transdermal system. The currently available formulations of oxybutynin are the subject of this review.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Oxybutynin	Cytochrome P450 3A4	Protein	Humans	Unknown	Substrate Inhibitor	Details